Citation

Melatonin is involved in the control of various physiological functions, such as sleep, cell growth and free radical scavenging. The ability of melatonin to behave as an antioxidant, together with the fact that the Alzheimer-related amyloid -peptide (A) triggers oxidative stress through hydroxyl radical-induced cell death, suggests that melatonin could reduce Alzheimer’s pathology. Although the exact etiology of Alzheimer’s disease (AD) remains to be established, excess A is believed to be the primary contributor to the dysfunction and degeneration of neurons that occurs in AD. A peptides are produced via the sequential cleavage of -secretase -site APP-cleaving enzyme 1 (BACE1) and -secretase (PS1/PS2), while -secretase (ADAM10) prevents the production of A peptides. We hypothesized that melatonin could inhibit BACE1 and PS1/PS2 and enhance ADAM10 expression. Using the human neuronal SH-SY5Y cell line, we found that melatonin inhibited BACE1 and PS1 and activated ADAM10 mRNA level and protein expression in a concentration-dependent manner and mediated via melatonin G protein-coupled receptors. Melatonin inhibits BACE1 and PS1 protein expressions through the attenuation of nuclear factor-B phosphorylation (pNF-B). Moreover, melatonin reduced BACE1 promoter transactivation and consequently downregulated -secretase catalytic activity. The present data show that melatonin is not only a potential regulator of /-secretase but also an activator of -secretase expression through the activation of protein kinase C, thereby favoring the nonamyloidogenic pathway over the amyloidogenic pathway. Altogether, our findings suggest that melatonin may be a potential therapeutic agent for reducing the risk of AD in humans.